Intuitive Surgical Stock Is Up Over 400%. Here's Why It's Still a No-Brainer Buy.

Intuitive Surgical’s installed base grew to 11,395 systems in Q1 2026, while surgeries on da Vinci systems rose 17% year over year. The stock is still up more than 400% over the past decade but remains over 30% below its all-time high, with a current P/E of about 49x versus a five-year average near 69x. The article frames the pullback as a potential buying opportunity for aggressive growth investors, though it emphasizes the stock’s history of deep drawdowns.

Analysis

The market is treating ISRG as a high-multiple growth stock, but the more important debate is whether the recurring consumables/service mix deserves a software-like durability premium. That cash-flow profile is exactly what makes the name resilient through drawdowns: each incremental robot raises the installed base, which compounds procedure volume and locks in accessory demand with far less cyclicality than headline system sales suggest. The second-order implication is that competitors have to disrupt the ecosystem, not just win one hospital purchase, which raises the bar for any challenger in surgical robotics.

The current setup looks more like a sentiment reset than a fundamentals reset. A 30%+ drawdown against a still-expanding installed base and procedure throughput typically compresses forward expectations faster than operating reality deteriorates, especially when the core business can keep compounding for several years without needing a re-acceleration narrative. The key risk is not a collapse in usage, but multiple compression if investors decide the penetration curve is maturing faster than expected or if hospital capex scrutiny delays system placements for 1-2 quarters.

The contrarian read is that the market may be underpricing the optionality embedded in a platform that monetizes utilization, not just unit shipments. If procedure growth continues to outpace system growth, the earnings quality improves even if top-line optics look less dramatic, and that can support a re-rating once growth investors regain confidence. Still, this is a duration trade: the stock can stay cheap versus its own history longer than momentum holders expect, so timing matters more than conviction here.

Key Decisions for Investors

• Buy ISRG on further weakness into the next 2-6 weeks, using a tiered entry; target a 15-25% rebound if the market re-prices recurring revenue durability, but cut if procedure growth decelerates for two consecutive quarters.
• Express a relative-value long ISRG / short a broad healthcare-device basket over 3-6 months; the asymmetry favors ISRG if utilization growth keeps outpacing system growth, while the short leg buffers multiple risk.
• For options, use a call spread in ISRG rather than outright calls: 6-12 month upside participation with defined risk, since the main hazard is sideways-to-lower compression rather than immediate fundamental deterioration.
• Avoid chasing on strength above the current multiple until management confirms no slowdown in installed-base monetization; if forward P/E re-expands before results, the risk/reward deteriorates quickly.
• If looking for a hedge, pair long ISRG with short NVDA only as a factor trade if portfolio is overexposed to long-duration growth; otherwise ignore NVDA here since the article offers no real fundamental linkage.